Gufic BioSciences Reports Declining Financial Metrics Amid Rising Interest Expenses in March 2025

Gufic BioSciences has reported its financial results for the quarter ending March 2025, revealing significant challenges within its operations. The company's evaluation has undergone notable changes, with its score reflecting a decline to -24 from -12 over the past three months.
Key metrics indicate a concerning trend for Gufic BioSciences. The operating profit to interest ratio has reached its lowest point at 3.14 times, showing a consistent decline over the last five quarters, which raises questions about the company's capacity to manage its interest obligations. Profit before tax (PBT) has also shown a substantial reduction, recorded at Rs 10.13 crore, which is significantly lower than the average of Rs 26.66 crore from the previous four quarters. Similarly, profit after tax (PAT) has decreased to Rs 7.72 crore, down from an average of Rs 20.50 crore, indicating a troubling trajectory for profitability.

Additionally, the company has experienced a sharp rise in interest expenses, now at Rs 8.40 crore, marking the highest level in the last five quarters. This increase in interest costs suggests a reliance on higher borrowings, further complicating the financial landscape for Gufic BioSciences.

Overall, the recent financial results highlight a challenging environment for the company, prompting a revision in its score.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.